Motif Bio (MTFB.L): Further clinical trial data required for iclaprim approval | Collagen Solutions (COS.L): Result of General Meeting and Open Offer


Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SPA Healthcare - Morning Comment
- Published:
06 Jun 2019 -
Author:
Vadim Alexandre | Liam Gascoigne-Cohen -
Pages:
3 -
Motif Bio (MTFB.L): Further clinical trial data required for iclaprim approval | Collagen Solutions (COS.L): Result of General Meeting and Open Offer